United States: The Safe Harbor Provision Of 35 U.S.C. § 121 Against Double Patenting Rejections Just Got A Little Less Safe

Ever since the Federal Circuit held that a later-issuing but earlier-expiring patent could serve as an obviousness-type double patenting (OTDP) reference in Gilead Sciences, Inc. v Natco Pharma Ltd., 753 F.3d 1208 (Fed. Cir. 2011), Applicants and Patentees have found themselves facing many more double patenting rejections. Even continuing applications filed in a single portfolio run the risk of receiving OTDP rejections if the claims of the subject and reference patents are not patentably distinct. See AbbVie Inc. v. Kennedy Inst. of Rheumatology, 764 F.3d 1366 (Fed. Cir. 2014). The court in Kennedy explained (in dicta) that patents sharing a common priority chain "still can have different patent terms due to examination delays at the PTO." AbbVie, 764 F.3d at 1373. So, patent term adjustment accumulated during examination could be in jeopardy when the subject claims overlap those in a continuation.

With patent term adjustment in the Federal Circuit's crosshairs, divisional applications and their safe harbor protection against double patenting rejections under 35 U.S.C. § 121 have assumed a sudden new importance. Generally speaking, the Federal Circuit has allowed divisional applications to avoid OTDP rejections in most scenarios, as long as the subject application was formally labeled a divisional and the claims that issued were consonant with those withdrawn from an earlier case pursuant to a restriction requirement. But a recent Patent Trial and Appeal Board (PTAB) decision has called even the limited protection for divisional applications into question when intervening continuations are thrown into the mix. Ex Parte Sauerberg, Appeal 2015-007064 (PTAB Jan. 10, 2017).

Background on Obviousness-Type Double Patenting and the Safe Harbor Provision

35 U.S.C. § 121 provides statutory protection from double patenting rejections for a divisional application filed as a result of a restriction requirement:

A patent issuing on an application with respect to which a requirement for restriction under this section has been made, or on an application filed as a result of such a requirement, shall not be used as a reference either in the Patent and Trademark Office or in the courts against a divisional application or against the original application or any patent issued on either of them, if the divisional application is filed before the issuance of the patent on the other application.

The Federal Circuit has repeatedly addressed the scope of this "safe harbor" protection against OTDP, explaining that a reference patent must comply with certain formality and substantive features in order to qualify for protection. First, the reference patent must be labeled a divisional and not a continuation or continuation-in-part. Pfizer, Inc. v. Teva Pharm. USA, Inc., 518 F.3d 1353 (Fed. Cir. 2008); Amgen Inc. v. Hoffman-La Roche Ltd, 580 F.3d 1340 (Fed. Cir. 2009). An applicant must claim divisional status during examination and generally cannot correct this later by reissue. G.D. Searle LLC v. Lupin Pharm., Inc. 790 F.3d 1349 (Fed. Cir. 2015). In addition to formally identifying a patent as a divisional, the issued claims must also be consonant with an independent and distinct invention withdrawn from the parent application pursuant to a restriction requirement. Geneva Pharms., Inc. v. Glaxosmithkline Plc, 349 F.3d 1373 (Fed. Cir. 2003). Protection can be lost if intervening cases present inconsistent claims or receive irreconcilable restriction requirements. Bristol-Myers Squibb Co. v. Pharmachemie B.V., 361 F.3d 1343 (Fed. Cir. 2004).

In general, the Federal Circuit has tended to treat patentees leniently when they introduced nuances but otherwise complied with the formal and substantive requirements mentioned above. For instance, the court has explained that applicants need not immediately cover all inventions restricted out of a parent case in one single divisional. Rather, an applicant may file a series of divisional applications directed to different inventive groups identified in an original restriction requirement while retaining safe harbor protection. Boehringer Ingelheim Int'l. GmbH v. Barr Labs., Inc., 592 F.3d 1340 (Fed. Cir. 2010). Likewise, the court has explained that continuations descending from divisional applications can retain safe harbor protection over the original parent case that received the restriction requirement. Symbol Techs., Inc. v. Opticon, Inc., 935 F.2d 1569 (Fed. Cir. 1991); see also Amgen Inc. v. F. Hoffman-La Roche Ltd, 580 F.3d 1340 (Fed. Cir. 2009).

PTAB Decision in Ex Parte Sauerberg

Given this trend in the case law, the Sauerberg applicants must have felt fairly confident in their safe harbor eligibility when they filed a "divisional" application after a series of continuations of an original application that received a restriction requirement. After all, the Federal Circuit had previously confirmed that a subject patent could retain protection even when separated from the case that received an original restriction requirement by a chain of intervening divisional applications. The court had even extended protection to continuations filed from those divisional applications. But despite this body of precedent, the PTAB held in Sauerberg that a divisional filed from a continuation (rather than a divisional filed from another divisional, or a continuation filed from a divisional) was an entirely different scenario and denied safe harbor protection.

As background, in 2008 Sauerberg et al. filed a patent application directed to a genus of small molecule compounds and methods of treatment using those compounds ("original application"). In response to a restriction requirement between those two groups, the applicants elected the compound claims. The applicants serially filed two subsequent continuations (CON-1 and CON-2) with further compound claims, and then finally filed a divisional from the second continuation with claims directed to methods of treatment. The original application, CON-1, and CON-2 all issued as patents. The examiner rejected the divisional for double patenting over all three earlier patents and the applicants appealed.

On appeal, the PTAB first addressed the two continuations. While agreeing that "there is no requirement under § 121 that the divisional application being shielded by the safe harbor must immediately follow the parent," the Board explained that safe harbor only applied when the reference patents at issue were filed "as a result of a restriction requirement." Because the applicants could not show that they filed the two continuations in response to a requirement from the examiner to restrict the claims, safe harbor did not apply. The Board did not explain how they reconciled their holding with the protection extended by the Federal Circuit to continuations filed from divisional applications.

Turning to the original application, the Board pointed to the Federal Circuit's instructions in Lupin to narrowly apply the safe harbor provisions using a "strict test" (albeit in a different context involving reissue of a CIP application to switch its designation to a divisional). Based on that "strict test" and a narrow reading of § 121, the Board concluded that a divisional application must be filed before the original application that received a restriction requirement grants, rather than at any time during the pendency of an application that claims priority back to that original application. Thus, the Sauerberg applicants missed their window of opportunity to rely on safe harbor protection because the divisional application was filed from CON-2, long after the original application had issued as a patent.

It remains an open question whether the PTAB's interpretation of § 121 will withstand Federal Circuit scrutiny. Nevertheless, in light of the decision, it would be prudent for applicants to file at least one divisional during the pendency of any application that receives a restriction requirement in order to preserve the opportunity to argue for safe harbor protection.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
22 Jan 2019, Webinar, Washington, DC, United States

As part of Strafford Publications’ webinar series, Finnegan partners Shana Cyr and Mark Feldstein will provide essential updates on FDA practice and patent law relating to biologics and biosimilars.

27 Jan 2019, Other, Washington, DC, United States

Finnegan is a sponsor of the Association of Corporate Patent Counsel Winter Meeting. Finnegan partner Erika Arner will join the panel discussion “PTAB Review & Litigation.”

27 Jan 2019, Other, Florida, United States

Finnegan is a sponsor of the Association of Corporate Patent Counsel Winter Meeting. Finnegan partner Erika Arner will join the panel discussion “PTAB Review & Litigation.

Similar Articles
Relevancy Powered by MondaqAI
Marshall, Gerstein & Borun LLP
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Marshall, Gerstein & Borun LLP
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions